3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase NA
4
Phase 3
4
Phase 1/2
2
Phase EARLY_PHASE1
1
Phase 4
1
Phase 2/3
1
Phase 1
1
Status
Withdrawn
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Motor Activity
1
Lymphoma
1
Leukemia
1
Interventions
Magnetic Resonance Spectroscopy
17
Cyclophosphamide
16
fludarabine
12
Specimen Handling
12
Fluorodeoxyglucose F18
7
pembrolizumab
6
X-Rays
6
Nivolumab
6
Temozolomide
5
Radiotherapy
5
Immunotherapy, Adoptive
5
lenvatinib
4
Paclitaxel
4
Leukapheresis
4
Immune Checkpoint Inhibitors
4
Etoposide
4
Cisplatin
4
Carboplatin
4
ruxolitinib
3
fluciclovine F-18
3
Tirzepatide
3
Surgical Procedures, Operative
3
Doxorubicin
3
Dasatinib
3
Cholecalciferol
3
Biopsy
3
68Ga-FAPI
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
tislelizumab
2
palbociclib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
Recruiting
×
Tablets
×
Clear all
NCT06643221
2024-10-16
Allo-X
University of Arizona
Phase EARLY_PHASE1
Recruiting
100 enrolled